PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18413496-4 2008 Pioglitazone treatment led to improvement in levels of multiple cardiovascular risk markers, including high-sensitivity C-reactive protein, apolipoprotein B, apolipoprotein A1, high-density lipoprotein (HDL) cholesterol, triglyceride, insulin, and free fatty acid. Pioglitazone 0-12 apolipoprotein B Homo sapiens 140-156 19646194-7 2009 There was a decrease in VLDL triglyceride/apoB (P = 0.04) in the pioglitazone group. Pioglitazone 65-77 apolipoprotein B Homo sapiens 42-46 16644631-8 2006 At week 12, muraglitazar and pioglitazone reduced mean plasma triglyceride (-28 vs. -14%), apolipoprotein B (-12 vs. -6%), and non-HDL cholesterol (-6 vs. -1%) and increased HDL cholesterol (19 vs. 14%), respectively (P < 0.0001 vs. pioglitazone for all comparisons). Pioglitazone 29-41 apolipoprotein B Homo sapiens 91-107 17229249-7 2007 Significant total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B improvement was observed in pioglitazone group after 12 months, but not in the rosiglitazone group. Pioglitazone 190-202 apolipoprotein B Homo sapiens 145-161 12809958-11 2003 Pioglitazone 45 mg also significantly reduced serum triglycerides, apolipoprotein B, and total cholesterol:HDL-C ratio versus placebo (P = 0.007, P = 0.015, and P = 0.005, respectively). Pioglitazone 0-12 apolipoprotein B Homo sapiens 67-83 12466345-9 2002 HDL-cholesterol was increased and apolipoprotein B was decreased to a significantly greater extent with pioglitazone. Pioglitazone 104-116 apolipoprotein B Homo sapiens 34-50